Mesenchymal stromal cells and their secreted extracellular vesicles as therapeutic tools for COVID-19 pneumonia?
J Control Release
; 325: 135-140, 2020 09 10.
Article
in English
| MEDLINE | ID: covidwho-626153
ABSTRACT
The COVID-19 epidemic represents an unprecedented global health emergency, further aggravated by the lack of effective therapies. For this reason, several clinical trials are testing different off-label drugs, already approved for other pathologies. Mesenchymal stem/stromal cells (MSCs) have been tested during the last two decades for the treatment of various pathologic conditions, including acute and chronic lung diseases, both in animal models and in patients. In particular, promising results have been obtained in the experimental therapy of acute respiratory distress syndrome, which represents the most threatening complication of COVID-19 infection. Furthermore, more recently, great interest has been devoted to the possible clinical applications of extracellular vesicles secreted by MSCs, nanoparticles that convey much of the biological effects and of the therapeutic efficacy of their cells of origin. This review summarizes the experimental evidence underlying the possible use of MSCs and of MSC-EVs in severe COVID-19 infection and underlines the need to evaluate the possible efficacy of these therapeutic approaches through controlled studies under the supervision of the Regulatory Authorities.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia
/
Pneumonia, Viral
/
Coronavirus Infections
/
Mesenchymal Stem Cell Transplantation
/
Mesenchymal Stem Cells
/
Extracellular Vesicles
Type of study:
Experimental Studies
/
Prognostic study
Topics:
Long Covid
Limits:
Animals
/
Humans
Language:
English
Journal:
J Control Release
Journal subject:
Pharmacology
Year:
2020
Document Type:
Article
Affiliation country:
J.jconrel.2020.06.036
Similar
MEDLINE
...
LILACS
LIS